Conecte-se

Bibliografias temáticas / Cystic fibrosis Gene therapy / Livros

Siga este link para ver outros tipos de publicações sobre o tema: Cystic fibrosis Gene therapy.

Livros sobre o tema "Cystic fibrosis Gene therapy"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 11 de fevereiro de 2022

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores livros para estudos sobre o assunto "Cystic fibrosis Gene therapy".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os livros das mais diversas áreas científicas e compile uma bibliografia correta.

1

Love, Cynthia B. Genetic testing for cystic fibrosis: January 1989 through February 1997 : 1224 citations. Bethesda, Md. (8600 Rockville Pike, Bethesda 20894): U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1997.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

United States. Congress. Senate. Committee on Small Business. Research on childhood diseases by entrepreneurs: Hearing before the Committee on Small Business, United States Senate, One Hundred Third Congress, second session ... Thursday, May 26, 1994. Washington: U.S. G.P.O., 1995.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

United States. Congress. Senate. Committee on Small Business. Research on childhood diseases by entrepreneurs: Hearing before the Committee on Small Business, United States Senate, One Hundred Third Congress, second session ... Thursday, May 26, 1994. Washington: U.S. G.P.O., 1995.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Skypala, Isabel. Eating well with cystic fibrosis. Bromley: Cystic Fibrosis Trust, 1994.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Tsui, Lap-Chee, Giovanni Romeo, Rainer Greger e Sergio Gorini, eds. The Identification of the CF (Cystic Fibrosis) Gene. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5934-0.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Ferguson, Kate. The physical treatment of cystic fibrosis. Bromley: Cystic Fibrosis Trust, 1995.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Mofford, K. A. Preclinical studies in DNA/liposome gene transfer for cystic fibrosis. Oxford: Oxford Brookes University, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

MacDonald, Anita. Eating well with cystic fibrosis: A guide for children and parents. Bromley: Cystic Fibrosis Trust, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

1932-, Elston Robert C., ed. Multipoint mapping and linkage based upon affected pedigree members: Genetic Analysis Workshop 6, proceedings of a workshop held at Gulf Park, Long Beach, Mississippi, October 10-12, 1988. New York: Liss, 1988.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Duguay, François. Use of the Xenopus oocyte as a potential expression system for the cystic fibrosis gene. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1991.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Li, Xiaobin. Characterization of multiple copies of a DNA segment containing cystic fibrosis transmembrane conductance regulator gene exon 9 in the human genome. Ottawa: National Library of Canada, 1999.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Association, American Diabetes, ed. American Diabetes Association guide to medical nutrition therapy for diabetes. 2^a ed. Alexandria, Va: American Diabetes Association, 2012.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Lee, Benjamin Haeyul. Gene delivery to human sweat glands: A model for cystic fibrosis gene therapy. 2006.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Ryan, Jeanne. Charisma. Simon & Schuster, Limited, 2016.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Charisma. 2015.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Sayer, John A., e Roslyn J. Simms. Nephronophthisis. Editado por Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0317_update_001.

Texto completo da fonte

Resumo:

Nephronophthisis (NPHP) is a clinically heterogeneous autosomal recessive cystic kidney disease and the leading genetic cause of end-stage renal failure in children and young adults. Whilst enlarged dysplastic cystic kidneys are associated with infantile NPHP, more typically renal ultrasound reveals normal kidney size and corticomedullary cysts in a child with polyuria and secondary enuresis. Extrarenal manifestations occur in 10–15% including retinal degeneration, cerebellar vermis hypoplasia and liver fibrosis, requiring referral to other specialists. Mutations in 18 genes have been identified to cause NPHP, but a genetic diagnosis still cannot be found in many patients. NPHP is classified as a ciliopathy because of the localization of the protein products of the associated genes. Currently there is no specific therapy for NPHP.

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

National Heart, Lung, and Blood Institute, ed. Facts about cystic fibrosis. [Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute, 1995.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Thursfield, Rebecca, Chris Orchard, Rosanna Featherstone e Jane C. Davies. Future treatments. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198702948.003.0013.

Texto completo da fonte

Resumo:

There are only a relatively limited armoury of drugs, the majority of which are aimed at downstream symptoms of cystic fibrosis. Therapies targeting the basic defect in CF as well as continued availability of more conventional drugs are required. Progress in gene therapy has been limited by the significant barriers to gene transfer of the CF lung, but the UK is hosting a large repeated dose trial of nebulized non-viral gene therapy designed around clinically meaningful outcomes. The UK CF Gene Therapy Consortium is also seeking to develop a promising modified lentiviral approach, although this is some years off. Perhaps the exciting development of recent decades has come from small molecule CFTR modulators, driven by an understanding of basic pathophysiological mechanisms. Ivacaftor is the first drug to be licensed, having proved itself highly clinically efficacious in patients with the class-3 gating mutation G551D. The trial pipeline seeks to expand indications for this and to explore the potential of Phe508del correctors. Finally, a number of anti-inflammatory and anti-infective strategies are being pursued. The emerging global problem of antibiotic resistance is leading to exciting alternatives such as biofilm disruption and bacteriophage to be explored.

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Beattie, R. Mark, Anil Dhawan e John W.L. Puntis. Cystic fibrosis. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198569862.003.0021.

Texto completo da fonte

Resumo:

Gastrointestinal manifestations 156Management of gastrointestinal symptoms in children with CF 158Nutrition in CF 158Nutritional management 159Vitamins 160The incidence of cystic fibrosis (CF) is around 1 in 2500. Cases are diagnosed as a consequence of population screening or high-risk screening, or following presentation with clinical symptoms typical of the disorder. The basic defect is in the CFTR (cystic fibrosis transmembrane conductance regulator) protein which codes for a cyclic adenosine monophosphate-regulated chloride transporter in epithelial cells of exocrine organs. This is involved in salt and water balance across epithelial surfaces. The gene is on chromosome 7. There are multiple known mutations, the most common being ...

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Lap-Chee, Tsui, ed. The Identification of the CF (cystic fibrosis) gene: Recent progress and new research strategies. New York: Plenum Press, 1991.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Cystic Fibrosis: Medical Care. Lippincott Williams & Wilkins, 2000.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

(Editor), Lap-Chee Tsui, Giovanni Romeo (Editor), Rainer Greger (Editor) e Sergio Gorini (Editor), eds. The Identification of the CF (Cystic Fibrosis) Gene: Recent Progress and New Research Strategies (Advances in Experimental Medicine and Biology). Springer, 1991.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Watson, Ronald Ross. Diet and Exercise in Cystic Fibrosis. Elsevier Science & Technology Books, 2014.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Molecular Basis and Gene Therapies of Cystic Fibrosis. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03943-684-2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Beattie, R. Mark, Anil Dhawan e John W.L. Puntis. Cystic fibrosis-associated liver disease. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198569862.003.0022.

Texto completo da fonte

Resumo:

Pathophysiology 162Clinical features 162Diagnosis 163Management 164Cystic fibrosis (CF) is an autosomal recessive disease resulting from mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) (see Chapter 21). CFTR functions as a transmembrane chloride channel in the apical membrane of most secretory epithelia and the disease thus affects lungs, pancreas, exocrine glands, gut, and liver. In CF-associated liver disease the biliary tract is most commonly involved in a spectrum from asymptomatic to biliary cirrhosis. The liver disease runs from mild and subclinical to severe cirrhosis and portal hypertension. Clinical disease is seen in 4–6% of cases, but there are biochemical abnormalities in 20–50%. At autopsy, fibrosis is present in 20% and steatosis in 50%....

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

US GOVERNMENT. Cystic Fibrosis and DNA Tests: Implications of Carrier Screening. Office of Technology Assessment, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

United States. Congress. Office of Technology Assessment., ed. Cystic fibrosis and DNA tests: Implications of carrier screening. Washington, DC: Congress of the U.S., Office of Technology Assessment, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Cystic Fibrosis: A Trilogy of Biochemistry, Physiology, and Therapy. Cold Spring Harbor Laboratory Press, 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Carsten, Schultz, ed. Defects of secretion in cystic fibrosis. New York: Springer, 2005.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

1945-, Orenstein David M., e Stern Robert C. 1938-, eds. Treatment of the hospitalized cystic fibrosis patient. New York: M. Dekker, 1998.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

United States. Congress. Office of Technology Assessment., ed. Cystic fibrosis and DNA tests: Implications of carrier screening : summary. Washington, D.C: Congress of the U.S., Office of Technology Assessment, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Kriemler, Susi. Exercise, physical activity, and cystic fibrosis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199232482.003.0033.

Texto completo da fonte

Resumo:

Cystic fibrosis (CF) is the most common genetic autosomal recessive disease of the Caucasian race, generally leading to death in early adulthood.1 The frequency of the gene carrier (heterozygote) is 1:20–25 in Caucasian populations, 1:2000 in African-Americans, and practically non-existent in Asian populations. The disease occurs in about 1 in every 2500 life births of the white population. Mean survival has risen from 8.4 years in 1969 to 32 years in 2000 due to improvements in treatment. The genetic defect causes a pathological electrolyte transport through the cell membranes by a defective chloride channel membrane transport protein [cystic fibrosis transmembrane conductance regulator (CFTR)]. With respect to the function, this affects mainly the exocrine glands of secretory cells, sinuses, lungs, pancreas, liver, and the reproductive tract of the human body leading to a highly viscous, water-depleted secretion. The secretion cannot leave the glands and in consequence causes local inflammation and destruction of various organs. The main symptoms include chronic inflammatory pulmonary disease with a progressive loss of lung function, exocrine and sometimes endocrine pancreas insufficiency, and an excessive salt loss through the sweat glands.1 A summary of the signs and symptoms of CF will be given with a special emphasis on the effect of exercise performance and capacity.

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Heather, Nicky. Nutritional management of cystic fibrosis. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198759928.003.0024.

Texto completo da fonte

Resumo:

This chapter covers the nutritional management of cystic fibrosis. This includes discussion of the risk factors for malnutrition, assessment of nutritional status, assessment of nutritional requirements, and practical management. The chapter includes a section on pancreatic enzyme replacement therapy.

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Cystic Fibrosis Pulmonary Infections: Lessons from Around the World. Birkhäuser, 2012.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

A, Bauernfeind, Marks Melvin I e Strandvik B, eds. Cystic fibrosis pulmonary infections: Lessons from around the world. Basel: Birkhauser Verlag, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

United States. Congress. Office of Technology Assessment., ed. Genetic counseling and cystic fibrosis carrier screening: Results of a survey. Washington, DC: Congress of the U.S., Office of Technology Assessment, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

US GOVERNMENT. Genetic Counseling and Cystic Fibrosis Carrier Screening: Results of a Survey (Background Paper). Office of Technology Assessment, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Cuppens, Harry. Genetic Studies of the Cystic Fibrosis Transmembrane Conductance Regulator Gene in Belgian Cf Patients. Coronet Books Inc, 1995.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Multipoint mapping and linkage based upon affected pedigree members: Genetic Analysis Workshop 6, proceedings of a workshop held at Gulf Park, Long Beach, ... in clinical and biological research). Liss, 1989.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Cystic Fibrosis Pulmonary Infections: Lessons from Around the World (Respiratory Pharmacology and Pharmacotherapy). Birkhauser, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

(Editor), Adolf Bauernfeind, Melvin I. Marks (Editor) e Brigitta Strandvik (Editor), eds. Cystic Fibrosis Pulmonary Infections: Lessons from Around the World (Respiratory Pharmacology and Pharmacotherapy). Birkhauser, 2004.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Cole, Desmond. CBD Oil for Cystic Fibrosis: Alternative Therapy for the Management and Treatment of Liver Fibrosis Using CBD Oil. Independently Published, 2019.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Pitt, Tyrone. Antibiotic Resistance in Systic Fibrosis - an Emerging Crisis? (International Congress and Symposium). Editado por Tyrone Pitt. Royal Society of Medicine Press, 2003.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Burmer, Karl. CBD Oil for Cystic Fibrosis: Effective Therapy for Severe Damage in the Lung and Digestive System. Independently Published, 2019.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Strategies for Pharmacokinetic Optimization of Continuous Infusion Therapy of Ceftazidime and Aztreonam in Patients with Cystic Fibrosis. CIP-DATA, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Slack, Jonathan. 3. Mutations and gene variants. Oxford University Press, 2014. http://dx.doi.org/10.1093/actrade/9780199676507.003.0003.

Texto completo da fonte

Resumo:

All gene variants originate as mutations. Most variants in the genome of any given individual are not new mutations but have been inherited from previous generations. ‘Mutations and gene variants’ shows that mutations can occur in any cell of the body, but in order to be inherited they must occur in the DNA of the reproductive cells. There are numerous genetic diseases caused by a single mutation in one gene, and the examples considered here are cystic fibrosis, haemophilia, achondroplasia, and Holt-Oram Syndrome. In such cases, the inheritance of the abnormal gene variant follows simple Mendelian rules. The origin of cancer is explained as a combination of mutations occurring in a single cell of the body. Inherited gene variants predisposing to cancer do so because they reduce the number of new mutations required.

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Koch, Ch. Inhalation Therapy: Roche and Genentech Symposium European Cystic Fibrosis Conference, Paris, June 1994 (Respiration, Vol 62, Suppl 1). S. Karger AG (Switzerland), 1995.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

M, Geddes Duncan, ed. Colistin: New insights and practical issues : proceedings of a symposium held at the British Library, London, UK, on 27 January 2004. London: Royal Society of Medicine Press, 2004.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Recipes for the Specific Carbohydrate Diet: The Grain-Free, Dairy-Free, Sugar-Free Solution to IBD, Celiac Disease, Autism, Cystic Fibrosis, and other ... Conditions (Healthy Living Cookbooks). Fair Winds, 2008.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Michels, Virginia V. Genetics. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199755691.003.0276.

Texto completo da fonte

Resumo:

Genetic factors play a role in the development of many types of human disease. Genetic determinants may be chromosome abnormalities (Down syndrome, Kleinfelter syndrome, Turner syndrome), single gene defects (dilated and hypertrophic cardiomyopathies, Ehlers-Danlos syndrome, Marfan syndrome, neurofibromatosis, tuberous sclerosis, Gaucher disease, cystic fibrosis, sickle cell disease), mitochondrial mutations (MELAS, MERRF, Kearns-Sayre syndrome), or epigenetic or multifactorial factors. Genetics testing methods are also reviewed.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!